Three pooled trials, nearly 19,000 participants
This prespecified analysis brings together individual participant data from 18,991 people, including 6,664 women, who made up 35% of the sample. Two trials, FIDELIO-DKD and FIGARO-DKD, involved people with chronic kidney disease and type 2 diabetes. The third, FINEARTS-HF, focused on heart failure with mildly reduced or preserved ejection fraction.
The researchers compared several cardiovascular and kidney events, as well as mortality, by sex over a median follow-up of 2.9 years. They also investigated whether the effect of finerenone differed between women and men. The source material provides only the PubMed abstract, not the full text.
Fewer treatments despite advanced disease
Women were slightly older and more often had stage 4 cardiovascular-kidney-metabolic syndrome. At baseline, they were less likely to receive statins, renin–angiotensin system inhibitors, SGLT2 inhibitors or GLP-1 receptor agonists, among other treatments.
This gap alone does not demonstrate that every instance of non-prescribing was unjustified. The abstract does not allow individual indications, contraindications or reasons for the observed differences to be checked.
Different crude rates, but comparable adjusted risk
The rate of hospitalization for heart failure or cardiovascular death was 4.8 events per 100 person-years in women, compared with 3.9 in men. After statistical adjustment, the difference was no longer clear: the hazard ratio was 0.97, with a confidence interval of 0.89 to 1.06. Crude rates alone therefore do not establish a higher risk in women.
All-cause mortality, however, was lower in women after adjustment. For finerenone, the analyses detected no sex difference in its effect on cardiovascular events, kidney events or mortality. This absence of a detected difference does not prove that the effects are strictly identical.
Limitations to keep in mind
The comparison between women and men is not randomized, even though the data come from randomized trials. Unaccounted-for differences may remain after adjustment. These findings concern patients with advanced disease, not the general population. The full text, funding and conflicts of interest have not been checked.
What we can take away
Above all, this analysis calls for a closer look at gaps in care between women and men. It provides no evidence to support using finerenone differently based on sex alone.
Sources and provenance
- Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.
Source date: 2026-11-10.
Journal Article, Randomized Controlled Trial · Résumé PubMed uniquement, texte intégral non consulté


